Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

MERUS LABS INTERNATIONAL INC T.MSL

"Merus Labs International Inc is a specialty pharmaceutical company. The Company acquires and licenses novel pharmaceutical products."


TSX:MSL - Post by User

Comment by lscfaon Dec 08, 2015 12:48pm
94 Views
Post# 24365469

RE:RE:CIBC

RE:RE:CIBC Correction. 12 month target price is $3.98. Sintrom savings are $2 million/qtr or $8 million/yr....
lscfa wrote: I see $3.38 for 12 month target price based on 2016 exit rate ebitda.....

2016 Guidance $30 million (before acquisitions) + $8 million (acquisitions) + $2 million (Sintrom savings) = $40 million ebitda

Using CIBC's 10x multiple => $400 million enterprise value

$400 million - $62 million in debt = $338 million market cap

$338 million / 100 miliion shares = $3.38 share price



<< Previous
Bullboard Posts
Next >>